Добірка наукової літератури з теми "Patologie a cellule B"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Зміст
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Patologie a cellule B".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Patologie a cellule B"
Magistroni, Riccardo. "La ricerca oggi." Giornale di Clinica Nefrologica e Dialisi 25, no. 3 (July 10, 2013): 282–87. http://dx.doi.org/10.33393/gcnd.2013.1056.
Повний текст джерелаDi Lullo, A. M., M. Scorza, F. Amato, M. Comegna, V. Raia, L. Maiuri, G. Ilardi, E. Cantone, G. Castaldo, and M. Iengo. "An ex vivo model contributing to the diagnosis and evaluation of new drugs in cystic fibrosis." Acta Otorhinolaryngologica Italica 37, no. 3 (June 2017): 207–13. http://dx.doi.org/10.14639/0392-100x-1328.
Повний текст джерелаBasilico, Marcello. "L'autorizzazione giudiziale all'impianto di cellule staminali in pazienti affetti da patologie degenerative." QUESTIONE GIUSTIZIA, no. 1 (July 2014): 137–41. http://dx.doi.org/10.3280/qg2014-001011.
Повний текст джерелаAltavilla, Annagrazia, and Alessandro Dell’Erba. "La ricerca sulle cellule staminali: la nuova sfida dell’Europa unita." Medicina e Morale 53, no. 6 (December 31, 2004): 1133–78. http://dx.doi.org/10.4081/mem.2004.621.
Повний текст джерелаBarsotti, Nicola. "Biomeccanica umana, stress e immunità." PNEI REVIEW, no. 2 (November 2021): 63–76. http://dx.doi.org/10.3280/pnei2021-002006.
Повний текст джерелаCortese, Fabrizio, Leonardo Puddu, Domenico Mercurio, and Alessandro Santandrea. "Innesto di cellule mesenchimali su membrana nel trattamento delle patologie cartilaginee della tibio-tarsica." LO SCALPELLO-OTODI Educational 33, no. 3 (October 25, 2019): 304–10. http://dx.doi.org/10.1007/s11639-019-00341-z.
Повний текст джерелаLombardi, Duccio. "Decellularizzazione d'organo: matrici fisiologiche per la generazione di organi in vitro." Giornale di Clinica Nefrologica e Dialisi 25, no. 3 (August 26, 2013): 244–47. http://dx.doi.org/10.33393/gcnd.2013.1046.
Повний текст джерелаMalberti, Fabio. "Vitamina D nativa nei pazienti con malattia renale cronica non in trattamento dialitico." Giornale di Clinica Nefrologica e Dialisi 25, no. 2 (May 29, 2013): 107–11. http://dx.doi.org/10.33393/gcnd.2013.1018.
Повний текст джерелаDemori, Ilaria. "Microbiota e immunità." PNEI REVIEW, no. 2 (November 2021): 49–62. http://dx.doi.org/10.3280/pnei2021-002005.
Повний текст джерелаFerretti, E., E. Ognio, E. Di Carlo, C. Tripodo, D. Ribatti, C. Guarnotta, C. Sorrentino, M. Ponzoni, and V. Pistoia. "Secondo Workshop AIEOP... in Lab Catania, 19-20 Maggio 2011." Pediatric Reports 3, no. 11 (June 1, 2011): 1–68. http://dx.doi.org/10.4081/pr.2011.s1.
Повний текст джерелаДисертації з теми "Patologie a cellule B"
Capolla, Sara. "Use of immune-nanoparticles containig chemiotherapeutic agents for the treatment of B-cell malignancies." Doctoral thesis, Università degli studi di Trieste, 2015. http://hdl.handle.net/10077/10980.
Повний текст джерелаB-cell malignancies are a heterogeneous group of clinical conditions including indolent diseases such as Chronic Lymphocytic Leukemia (CLL) and highly aggressive lymphoproliferative disorders such as Burkitt’s lymphoma. B-cell malignancies treatments take advantage of dose-intensive chemotherapeutic regimens and immunotherapy via monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents and cause several adverse effects. Thus, we propose a novel therapeutic approach for the treatment of CLL and Burkitt’s lymphoma in which high-doses of the association of hydroxychloroquine and chlorambucil (HCQ/CLB) or fludarabine were loaded inside biodegradable nanoparticles (BNPs) coated with an anti-CD20 antibody. First of all, a Burkitt’s lymphoma cell line (BJAB), two CLL cell lines (MEC1 and EHEB) and cells purified from patients’ blood samples were used to confirm CD20 expression and to assess BNPs binding and internalization. These studies demonstrated BNPs ability to bind malignant B cells and to enter inside cells in a process different from endocytosis. Then, BNPs therapeutic effect was evaluated by MTT test, AnnV/PI assay and western blot to put in evidence apoptosis induction and autophagy inhibition. These experiments demonstrated drugs-loaded BNPs ability to kill malignant B cells with comparable effects than those obtained with free drugs whereas empty BNPs were practically ineffective. In vivo BNPs characterization included the evaluation of their toxicity, biodistribution and therapeutic effect. C57/BL mice were used to evaluate BNPs toxicity which was studied considering survival, loss of body weight and several tissue markers in the blood. Mice receiving 8 injections of free HCQ+CLB died in this experiment whereas animals challenged with the same amount of drugs encapsulated inside BNPs did not show toxic effects suggesting BNPs safety. The importance of antiCD20 antibody in the homing of BNPs was confirmed by in vivo Time-Domain Optical Imaging performed in localized B-cell malignancy-bearing mice. This analysis suggested the ability of antiCD20-conjugated BNPs to specifically target tumor B-cells, with a pick after 24-48 hours. On the contrary, untargeted BNPs localization inside tumor was significantly decreased. In this analysis it was also evident that the liver is the main site of BNPs’ elimination while in the other organs the presence of fluorescent BNPs was very low. Finally, BNPs ability to treat a new xenograft human/SCID leukemia and Burkitt’s lymphoma mouse model was studied. Drugs-loaded BNPs were able to improve HCQ/CLB efficacy in vivo allowing the cure of treated all Burkitt’s lymphoma-bearing mice and 3 out of 7 leukemia-bearing animals. All these data together put the basis for the potential use of BNPs in the treatment of B-cell malignancies.
I tumori a cellule B sono un gruppo eterogeneo di patologie che comprendono sia malattie indolenti, come la leucemia linfatica cronica (LLC), sia aggressive, come il linfoma di Burkitt. Il trattamento delle patologie a cellule B prevede sia l’utilizzo di chemioterapici (agenti alchilanti e analoghi delle purine) che di anticorpi monoclonali. Nonostante la varietà di terapie esistenti, l’efficacia di questi farmaci è limitata dalla mancata specificità per le cellule tumorali e dall’induzione di gravi effetti collaterali. Per ovviare ai limiti delle terapie attuali, è stato quindi proposto l’utilizzo di nanoparticelle coniugate con un anticorpo antiCD20, specifico per le cellule B, e contenenti alte concentrazioni di chemioterapici (idrossiclorochina e clorambucile o fludarabina). Le nanoparticelle sono state caratterizzate in vitro e in vivo durante questo progetto di dottorato. Inizialmente sono stati effettuati studi in vitro al fine di valutare l’espressione del CD20 sulla superficie di una linea cellulare di linforma di Burkitt (BJAB), due linee di LLC (MEC1 e EHEB) e cellule purificate da campioni di sangue di pazienti affetti da LLC. In seguito, il legame e l’internalizzazione delle nanoparticelle a queste cellule sono stati dimostrati suggerendo anche come le nanoparticelle vengano internalizzate attraverso un meccanismo diverso dall’endocitosi. L’effetto terapeutico in vitro delle nanoparticelle è stato valutato con test MTT, AnnessinaV/PI e tramite western blot al fine di evidenziare l’induzione di apoptosi e l’inibizione dell’autofagia, meccanismi attraverso cui i farmaci utilizzati sono noti agire. Questi esperimenti hanno dimostrato che le nanoparticelle cariche di chemioterapici sono in grado di uccidere le cellule B tumorali con effetti paragonabili a quelli ottenuti da pari concentrazioni di farmaci liberi dimostrando come il processo di produzione delle nanoparticelle non influisca sull’efficacia dei chemioterapici. Al contrario, nanoparticelle vuote non sono in grado di uccidere le cellule dimostrando la mancata tossicità dei polimeri da cui sono costituite. Dopo aver confermato il legame e l’internalizzazione delle nanoparticelle che inducono la morte delle cellule B tumorali, sono stati effettuati esperimenti in vivo tra cui studi di tossicità al fine di valutare eventuali effetti collaterali indotti dal trattamento, studi di biodistribuzione e la valutazione degli effetti terapeutici. Gli studi di tossicità sono stati effettuati in topi sani valutando parametri quali la perdita di peso, la sopravvivenza e la tossicità sistemica. Nanoparticelle cariche di farmaci presentano un profilo tossicologico sicuro mentre pari dosi di farmaci liberi inducono la morte di tutti gli animali trattati. Questi esperimenti dimostrano quindi come l’inserimento di farmaci all’interno di nanoparticelle prevenga gli effetti collaterali normalmente indotti dai chemioterapici. Secondariamente, sono stati effettuati studi di biodistribuzione di nanoparticelle coniugate o meno con un anticorpo antiCD20. Questi studi effettuati tramite Optical Imaging dimostrano come nanoparticelle coniugate con l’anticorpo antiCD20 si localizzino preferenzialmente nella massa tumorale in 24-48 ore in quantità maggiore rispetto a nanoparticelle non coniugate con l’anticorpo. Inoltre, da queste analisi risulta evidente come il fegato sia il maggiore sito di eliminazione delle nanoparticelle mentre in altri organi la presenza di nanoparticelle è molto bassa. Infine, un modello disseminato di linfoma di Burkitt e un modello di LLC sono stati sviluppati in topi SCID (Severe Combined ImmunoDeficiency) iniettando rispettivamente cellule BJAB intraperitoneo e cellule MEC1 endovena. I modelli sono stati caratterizzati e utilizzati per valutare la potenziale applicazione delle nanoparticelle nel trattamento di queste patologie. Questi studi hanno dimostrato come le nanoparticelle siano in grado di aumentare l’efficacia dei chemioterapici e di curare tutti i topi affetti da linfoma di Burkitt e 3/7 topi affetti da leucemia. Concludendo, questi risultati suggeriscono la potenziale applicazione delle nanoparticelle cariche di chemioterapici nel trattamento di LLC e linfoma di Burkitt.
XXVII Ciclo
1986
Fidilio, Annamaria. "Ruolo dell Inotuzumab Ozogamicin (CMC-544) nell induzione dell apoptosi in cellule CD22-positive di patologie linfoproliferative." Thesis, Università degli Studi di Catania, 2011. http://hdl.handle.net/10761/236.
Повний текст джерелаLabriji, Houriya Mestaghanmi. "Vitamine D3 et cellule B du pancréas endocrine." Bordeaux 1, 1986. http://www.theses.fr/1986BOR10572.
Повний текст джерелаLabriji, Mestaghanmi Houriya. "Vitamine D et cellule B du pancréas endocrine." Grenoble 2 : ANRT, 1986. http://catalogue.bnf.fr/ark:/12148/cb37598859v.
Повний текст джерелаFalcone, M. "LA RIPROGRAMMAZIONE DI ASTROCITI UMANI IN CELLULE NEURO-STAMINALI E NEURONI COME POSSIBILE STRUMENTO TERAPEUTICO PER LE PATOLOGIE NEUROLOGICHE." Doctoral thesis, Università degli Studi di Milano, 2012. http://hdl.handle.net/2434/169918.
Повний текст джерелаTouarin, Pauline. "Décryptage d'un nouveau mécanisme régulant l'assemblage/désassemblage de réseaux galectine-glycoconjugués au cours d'interactions cellule-cellule." Thesis, Aix-Marseille, 2019. http://theses.univ-amu.fr.lama.univ-amu.fr/191218_TOUARIN_918h49a473o639ntovr_TH.pdf.
Повний текст джерелаGalectins are bridging glycosylated molecules by their β-galactoside moieties, forming a network involved in many physiological functions. Extracellularly, galectins function has been mainly described through carbohydrate binding activity. The first example of a carbohydrate-independent interaction outside the cell concerns galectin-1 (Gal1) and its ligand, the pre-BCR. This interaction has a crucial role in B-cell development through the formation of a Gal1-dependent lattice between pre-BII and stromal cells. Our previous study revealed that Gal1 interacts with a motif of the pre-BCR (λ5-UR) on a surface adjacent to the Gal1 CBS (Carbohydrate Binding Site) and allows Gal1 to undergo selective affinity changes in its carbohydrate-binding activity in vitro.Using solution state on cell NMR spectroscopy, we investigated the effect of λ5-UR interactions on Gal1 binding activity for its physiological ligands expressed on pre-BII and stromal cell surfaces. We show that λ5-UR can specifically induce a ligand binding shift of Gal1 when bound to its cell surface ligands. We also identified one glycan epitope for which Gal1 increases its affinity upon λ5-UR interaction and deciphered the intermolecular contact changes induced by λ5-UR. In addition, glycan arrays screening combined to NMR relaxation data showed that λ5-UR changes the internal dynamics of specific Gal1 CBS residues resulting in the targeting of specific glycan epitopes. This cellular and structural NMR study ever conducted at atomic resolution for a member of the galectins demonstrates that Gal/unglycosylated protein interactions can act as physiological regulators of Gal1 lattice interactions at the cell surface
Thibault, Catherine. "Modifications fonctionnelles de la cellule b pancreatique chez le rat hyperglycemique." Paris 7, 1993. http://www.theses.fr/1993PA077212.
Повний текст джерелаPERUZZI, MARIANGELA. "Terapia cellulare e ingegneria tissutale nelle patologie ischemiche del miocardio: creazione di un miocardio artificiale per la rigenerazione cardiaca." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2009. http://hdl.handle.net/2108/1000.
Повний текст джерелаCell therapy for regeneration, has received extensive attention and the accumulated evidence from both pre-clinical and clinical studies suggests that it has the potential to restore heart function. However, the results from first clinical trials are mixed, with benefits ranging from absent to transient and, at most, marginal. These studies indicate that adult stem cells, whether muscular or bone marrow-derived, fail to generate new cardiomyocytes, capable to improve cardiac function. Emerging evidence suggests that several subpopulations of resident cardiac stem cells (CSCs) have the ability to differentiate into cardiac myocytes, vascular smooth muscle and endothelial cells. CSCs represent a logical source to exploit in cardiac regeneration therapy bacause, unlike other adult stem cells, they are likely to be intrinsecally programmed to generate cardiac tissue in vitro and to increase cardiac tissue viability in vivo. In addition, autologous CSCs can be employed avoiding ethical and immunological problems associated with the use of embryonic stem cells. Recently, a group of our network has successfully isolated CPCs/CSCs from small biopsies of human myocardium and expanded them ex vivo trough several generations without loosing differentiation potential into cardiomyocytes and vascular cells, bringing autologous transplantation of cardiac stem cells closer to clinical translation. However cell therapy in general suffers limitatations related to variable cell retention, survival and significant cell death or apoptosis, early after implantation in the diseased myocardium. Furthermore, cell transplantation may not always be suitable for catastrophic events like large myocardial damage. For this reason, hybrid therapies that incorporate tissue engineering are being developed as potentially new therapeutic approaches for repair of myocardial tissue. Tissue engineering (TE) involves seeding a biodegradable scaffold with cells that grow into morphologically recognizable tissue both in vitro and in vivo. Recent advances in cell culture and TE have facilitated the development of suitable cell-engineered biodegradable grafts. The optimal biomaterials and cell types, however, have not been identified. Our hypothesis is that autologous cardiac stem cells could represent the most efficient and reliable cell type to be used for an hybrid therapy (tissue engineering/stem cells) to restore myocardial function in ischemic myocardial desease. TE joints the physical replacement of the diseased structure with new cardiac tissue built from a biodegradable scaffold, with the regenerating activity of the optimal cell types. A bioengineered tissue graft (biocomplex) would be the ideal treatment to repair cardiac ischemic diseases. The possibility to compare the biological activity of the CSCs with other adult SCs, should definitely individuate and characterize the advantages and disadvantages of the best clinical applicable biocomplex. Moreover, the creation of the appropriate animal model and the realization of diagnostic protocols aimed to monitor the in vivo cell fate, will be used as pre-clinical background for large animals and phase I-II clinical studies.
Tchakarska, Guergana. "Les multiples rôles de la cycline D1 dans la cellule B et les hémopathies malignes chroniques B." Caen, 2010. http://www.theses.fr/2010CAEN3127.
Повний текст джерелаMultiple myeloma (MM) and mantle cell lymphoma (MCL) are characterized by cyclin D1 expression normally absent in the B-cell lineage. CCND1 encodes two mRNA isoforms, « a » and « b » by alternative splicing. The respective role of each protein in the B-cell transformation process remains unknown. By using various cellular models and gain- and loss-of-function strategies we report that : downregulation of CCND1 expression is not sufficient for cell proliferation arrest and cell death promotion ; ectopic expression of cyclin D1a inhibits mitochondrial activity through the recruitment of VDAC channel ; ectopic expression of cyclin D1b allows in vivo engraftment through the activation of neoangiogenesis ; cyclins D1a/b and K regulate cell metabolism
Escolar, Jean-Claude. "Hypothermie et sécrétion de l'insuline par la cellule B pancréatique du rat." Bordeaux 1, 1989. http://www.theses.fr/1989BOR10507.
Повний текст джерела